

UYLA Biotherapeutics C-Corp
1230 York Ave,
NY, NY, 10065

Marian Okondo
+1646-587-3328
<https://www.uylabiotech.com>
info@uylabiotech.com



Industry:

Biotech, Therapeutics
Women's health

Management:

Marian Okondo, MS
5th Year The Rockefeller
University - **Co-Founder**,
CEO
Elena Okondo, BA
President of WREPA
KENYA - **Co-Founder**,
COO

Advisory Board: TBD

Seeking Members

Scientific Advisory Board:

Seeking members with
expertise in-
Synthetic Biology
Women's Health

Number of Employee: 3

Finance:

Accounting/Tax: TBD

Funding to Date:

Founder- \$1000

Friends and Family -\$3000

Financing Sought: \$300K

For:

R&D

Operating costs

IP

Operating costs

IP(Seeking): Pending

Provisional Patent

Legal: TBD

Business Description/ Company Background

UYLA Biotherapeutics is a women's health startup, founded for the women close to us and globally, suffering from debilitating benign conditions affecting their daily lives. UYLA is harnessing synthetic biology technology to develop live biotherapeutic products for women's health conditions by building an engineered live biotherapeutic platform and our first indication is uterine fibroids.

The Problem

Uterine Fibroids are non-cancerous tumors of the uterus. This condition affects ~70% of women by the onset of menopause. 25-50% of premenopausal women are symptomatic and 25% have symptoms severe enough to warrant treatment. Uterine fibroid therapy is complicated and requires a costly multitherapy approach to have a long-term effect. Most medications used to treat uterine fibroids only manage the symptoms and have negative side effects. Fibroids are also the most common reason for unnecessary hysterectomies. To date, there is no long-term treatment that is non-hormonal and effective.

The Solution

UYLA Biotherapeutics is engineering a first-of-a-kind, non-invasive, non-hormonal, live biotherapeutic, targeted treatment to address uterine fibroids. Our product is a known tumor colonizing probiotic that we genetically engineered to deliver and release a therapeutic agent to the fibroid tumor. It directly gets to the fibroids and shrinks and kills them while also managing patients' symptoms without any of the hormonal side effects experienced from the current existing options.

Market Opportunity

The annual global market for uterine fibroid treatment market is valued at \$4.2B, and 1.2B for the US. The market is segmented by 1) invasive surgical and minimally invasive interventions and 2) medications used to treat uterine fibroids. The market is expected to grow by CARG of 8.7% in the next 5 years despite undertreatment and underdiagnosis. UYLA's therapeutic product will be promoted to women with severe to moderate uterine fibroid symptoms. In the US, we will also target the 12K busiest gynecologists and nurse practitioners that write 80% of the prescriptions.

Commercial/Milestones

UYLA biotherapeutics is currently at the basic research stage, we have identified our target, the therapeutic payload, and the live biotherapeutic chassis. We are currently applying for non-dilutive funds and grants for the proof-of-concept experiments. To advance to phase I we have identified potential partners to work with to develop and formulate our engineered probiotic platform for clinical use. Fundraising will happen at each stage of development. Finally, we will out license our proprietary product to biopharma and leverage their regulatory and commercialization expertise.

Competition/Competitive Advantage

UYLA biotherapeutics will develop the first non- hormonal, non-invasive and targeted therapy that can shrink fibroid tumors with no hormonal side effects to delay or prevent invasive/minimally invasive interventions.

Financial Forecasts: (Unaudited)

We anticipate approval by 2030. Financial projections are conservatively modeled against the hormonal analogs for uterine fibroids, Myfembree and Orihann, assuming upfront and milestone payments from collaborations or partnerships.

	2028	2029	2030	2031	2032
Revenue (in Thousands)		\$5,000	\$30,000	\$59,000	\$98,200
Operating Costs	\$23,000	\$37,000	\$20,000	\$20,000	\$20,000
Net Income	(\$23,000)	(\$32,000)	\$10,000	\$39,000	\$78,200